Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 13/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11956477 | 1.00 | KDM4E (0.43) | KDM4ETDP1POLBMEN1KMT2A | |
| SCHEMBL21105824 | 1.00 | KDM4E (0.43) | KDM4ETDP1POLBMEN1KMT2A | |
| SCHEMBL16543781 | 0.96 | KDM4E (0.40) | KDM4ETDP1POLBMEN1KMT2A | |
| SCHEMBL18592238 | 0.93 | KDM4E (0.40) | KDM4ETDP1POLBMEN1KMT2A | |
| SCHEMBL23872011 | 0.91 | MEN1 (0.44) | KDM4ETDP1POLBMEN1KMT2A | |
| SCHEMBL18592262 | 0.89 | MEN1 (0.37) | KDM4ETDP1POLBMEN1KMT2A | |
| SCHEMBL18592235 | 0.88 | KDM4E (0.39) | KDM4ETDP1POLBMEN1KMT2A | |
| SCHEMBL25925225 | 0.87 | KDM4E (0.36) | KDM4ETDP1POLBMEN1KMT2A | |
| SCHEMBL21214834 | 0.86 | MEN1 (0.41) | KDM4ETDP1POLBMEN1KMT2A | |
| SCHEMBL24764220 | 0.86 | KDM4E (0.42) | KDM4ETDP1POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| EP-4328219-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | YALE UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| WO-2023220425-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807693-B2 | Apelin polypeptides | AMGEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20080020978-A1 | CGRP peptide antagonists and conjugates | AMGEN INC. | 2008-01-24 | — | — | US | disclosed |
| US-20070269369-A1 | Modified Fc molecules | AMGEN INC. | 2007-11-22 | — | — | US | disclosed |
| US-7259137-B2 | Tumor necrosis factors; cytokines; immunoglobulins; autoimmune diseases | AMGEN INC. (US) | 2007-08-21 | — | — | US | disclosed |
| US-20070134245-A1 | Rankl antibody-PTH/PTHrP chimeric molecules | AMGEN INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070071764-A1 | conjugated polymer drug contains toxin protein and polyethylene glycol; treating autoimmune diseases, such as multiple sclerosis, type 1 diabetes, psoriasis, inflammatory bowel disease, dermatitis, rheumatoid arthritis, psoriasis; asthma, allergy, restinosis, fibrosis, scleroderma, glomerulonephritis | AMGEN INC. | 2007-03-29 | — | — | US | disclosed |
| US-7189827-B2 | Modified peptides as therapeutic agents | AMGEN INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7186810-B2 | Modified peptides as therapeutic agents | AMGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20070049532-A1 | Modified peptides as therapeutic agents | AMGEN INC. | 2007-03-01 | — | — | US | disclosed |
| US-7169905-B2 | Modified peptides as therapeutic agents | AMGEN INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7166707-B2 | Identifying peptide mimetic for treatment and prevention of tumors and autoimune diseases | AMGEN INC. (US) | 2007-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | KDM4E 1073/4885TDP1 409/4885POLB 845/4885 |
| US-20070049532-A1 | Modified peptides as therapeutic agents | FCGRT, FCGR3B, FCGR1A | KDM4E 3865/4885TDP1 1908/4885POLB 1944/4885 |
| US-20070071764-A1 | conjugated polymer drug contains toxin protein and polyethylene glycol; treating autoimmune diseases, such as multiple sclerosis, type 1 diabetes, psoriasis, inflammatory bowel disease, dermatitis, rheumatoid arthritis, psoriasis; asthma, allergy, restinosis, fibrosis, scleroderma, glomerulonephritis | F11, F13A1, F12 | KDM4E 3964/4885TDP1 884/4885POLB 817/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | KDM4E 1450/4885TDP1 985/4885POLB 4196/4885 |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | KDM4E 223/4885TDP1 151/4885POLB 22/4885 |
| US-20070269369-A1 | Modified Fc molecules | FCGR1A, FCGRT, FCGR2A | KDM4E 3673/4885TDP1 1321/4885POLB 539/4885 |
| US-20070134245-A1 | Rankl antibody-PTH/PTHrP chimeric molecules | PTH1R, TNFRSF9, TNFRSF1A | KDM4E 4029/4885TDP1 3982/4885POLB 3232/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885TDP1 236/4885POLB 2088/4885 |
| US-20080020978-A1 | CGRP peptide antagonists and conjugates | GRPR, CALCRL, CALCA | KDM4E 4510/4885TDP1 1408/4885POLB 3756/4885 |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | KDM4E 1205/4885TDP1 2137/4885POLB 3131/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885TDP1 236/4885POLB 2088/4885 |
| US-11807693-B2 | Apelin polypeptides | APLNR, FABP3, AP3B1 | KDM4E 4560/4885TDP1 4355/4885POLB 4706/4885 |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | CRBN, MDM2, UBE2N | KDM4E 498/4885TDP1 1896/4885POLB 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.